Table 1.

Studies of Stem cell transplant for PLL.

Study	Auto- vs. Allo-SCT	Status at transplant	Conditioning regimen	Donor status	OS (median), months	Relapse rate	Acute GVHD grade 2–4	Chronic GVHD—1 year	Treatment-related mortality
Krishan et al.	Auto	CR1 and CR2, PR	84% TBI based		52	60% at 1 year	–	–	6.6%
	Allo	CR1, PR	MAC—33% All TBI based RIC—67% Flu/Mel	MUD 58% MRD—42%	33	30.7% at 1 year	23%	–	30.7%
Kalaycio et al.	Allo	CR, PR 46% refractory disease	MAC—40% >500 cGy or >9 mg/kg Bu RIC—30% <500 cGy or <9 mg/kg Bu Neither—30%	MRD—23% MUD—49% MMUD—25% Ukn—2%	11.2	39% at 1 year	52%	42%	28%
Wiktor-Jedrzejczak et al.	Allo	CR, PR 50% refractory disease	TBI based 54% Chemo based—32% Unknown—14%	MRD—51% MUD—49%	12	41% at 3 years	39%	44%	41% at 3 years
Guillaume et al.	Allo	CR, PR, 11% refractory disease	MAC—41% RIC—59% TBI based—56% Chemo—44%	MRD—37% MUD—63%	26	47% at 3 years	51%	40%	31% at 3 years
Wiktor-Jedrzejczak et al., 2019	Allo	CR, PR	MAC—35% (>6 Gy) RIC—65% (<6 Gy) Only TBI based	MRD—43% MUD—57%	27.8	38% at 4 years	19%	43%	32% at 4 years
Dholaria et al.	Allo	CR, PR	MAC—73% Flu/Bu Pen/Bu RIC—27% Flu, Cy TBI Flu, Mel	MRD—46% MUD—27% MMUD—18% Cord—9%	56	23% at 4 years	28%	54%	32% at 4 years
Sellner et al.	Allo	CR, PR	Flu Cy—40% Flu/TBI—60%	MRD—40% MUD—40% MMUD—10% Haplo-10%	10	50% at 58 months	–	–	30% at 58 months

Allo, allogeneic; Auto, autologous; CR1, complete response 1; CR2, complete response 2; PR, partial response; TBI, total body irradiation; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; Flu, fludarabine; Mel, melphalan; Bu, busulfan; Pen, pentostatin; Cy, cyclophosphamide; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; Haplo, haplo-identical; Cord, cord blood; Ukn, Unknown.